{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:18:37Z","timestamp":1789373917621,"version":"build-2803163510"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:00:00Z","timestamp":1551484800000},"content-version":"vor","delay-in-days":1462,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/ki.2014.368","type":"journal-article","created":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T16:41:29Z","timestamp":1417624889000},"page":"516-526","source":"Crossref","is-referenced-by-count":31,"title":["Emerging treatments for amyloidosis"],"prefix":"10.1016","volume":"87","author":[{"given":"Rabya H.","family":"Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2014.368_bb0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1038\/ki.2014.368_bb0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00005792-199107000-00002","article-title":"Secondary systemic amyloidosis: response and survival in 64 patients","volume":"70","author":"Gertz","year":"1991","journal-title":"Medicine"},{"key":"10.1038\/ki.2014.368_bb0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/qjmed\/93.8.535","article-title":"Presentation, survival and prognostic markers in AA amyloidosis","volume":"93","author":"Joss","year":"2000","journal-title":"Q J Med"},{"key":"10.1038\/ki.2014.368_bb0025","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"key":"10.1038\/ki.2014.368_bb0030","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.368_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13506120600960288","article-title":"Structure, function and amyloidogenic propensity of apolipoprotein A-I","volume":"13","author":"Obici","year":"2006","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2007.06936.x","article-title":"Perspectives in treatment of AL amyloidosis","volume":"140","author":"Wechalekar","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1038\/ki.2014.368_bb0045","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.368_bb0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13506120701460923","article-title":"A primer of amyloid nomenclature","volume":"14","author":"Westermark","year":"2007","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0055","first-page":"245","article-title":"Amidoblack as a stain for hemoglobin","volume":"73","author":"Puchtler","year":"1962","journal-title":"Arch Pathol"},{"key":"10.1038\/ki.2014.368_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0076-6879(99)09003-5","article-title":"Staining methods for identification of amyloid in tissue","volume":"309","author":"Westermark","year":"1999","journal-title":"Methods Enzymol"},{"key":"10.1038\/ki.2014.368_bb0065","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MNH.0b013e3280bdc0db","article-title":"New insights into systemic amyloidosis: the importance of diagnosis of specific type","volume":"16","author":"Picken","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2014.368_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","article-title":"Amyloidosis","volume":"57","author":"Pepys","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1038\/ki.2014.368_bb0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nchembio.283","article-title":"A causative link between the structure of aberrant protein oligomers and their toxicity","volume":"6","author":"Campioni","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1038\/ki.2014.368_bb0080","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis","volume":"346","author":"Lachmann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.368_bb0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2012.108","article-title":"Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.368_bb0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/hrt.2009.190405","article-title":"Amyloid diseases of the heart: assessment, diagnosis, and referral","volume":"97","author":"Dubrey","year":"2011","journal-title":"Heart"},{"key":"10.1038\/ki.2014.368_bb0095","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"10.1038\/ki.2014.368_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0105","first-page":"837","article-title":"Tafamidis for the treatment of transthyretin-associated familial amyloid polyneuropathy. Expert Opinion in Orphan Drugs","volume":"1","author":"Schmidt","year":"2013"},{"issue":"Suppl 1","key":"10.1038\/ki.2014.368_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13506129.2012.678509","article-title":"The Diflunisal Trial: study accrual and drug tolerance","volume":"19","author":"Berk","year":"2012","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"Benson","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1038\/ki.2014.368_bb0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/13506120009146826","article-title":"Tabulation of transthyretin (TTR) variants as of 1\/1\/2000","volume":"7","author":"Connors","year":"2000","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0125","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plante-Bordeneuve","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1038\/ki.2014.368_bb0130","first-page":"6","author":"Dungu","year":"2012"},{"key":"10.1038\/ki.2014.368_bb0135","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.neurol.2013.07.030","article-title":"[Review of the recent literature on peripheral neuropathies: therapeutic advances","volume":"169","author":"Adams","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1038\/ki.2014.368_bb0140","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/ajkd.1998.v31.pm9631837","article-title":"Familiar amyloidotic polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits","volume":"31","author":"Lobato","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.368_bb0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0009-8981(02)00179-1","article-title":"Amyloid formation in rat transthyretin: effect of oxidative stress","volume":"323","author":"Tajiri","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.1038\/ki.2014.368_bb0150","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1038\/ki.2014.368_bb0155","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"10.1038\/ki.2014.368_bb0160","doi-asserted-by":"crossref","first-page":"76","DOI":"10.12968\/hmed.2010.71.2.46484","article-title":"Amyloid heart disease","volume":"71","author":"Dubrey","year":"2010","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1038\/ki.2014.368_bb0165","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/bi00173a029","article-title":"Synthesis and secretion of retinol-binding protein and transthyretin by cultured retinal pigment epithelium","volume":"33","author":"Ong","year":"1994","journal-title":"Biochemistry"},{"key":"10.1038\/ki.2014.368_bb0170","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAPmet30)","volume":"40","author":"Holmgren","year":"1991","journal-title":"Clin Genet"},{"issue":"Suppl 1","key":"10.1038\/ki.2014.368_bb0175","first-page":"188","article-title":"Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR)","volume":"18","author":"Wilczek","year":"2011","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.23521","article-title":"Liver transplantation and transthyretin amyloidosis","volume":"47","author":"Benson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1038\/ki.2014.368_bb0185","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13506120701614032","article-title":"Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation","volume":"14","author":"Lipeniks","year":"2007","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0190","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1006\/bbrc.2000.3203","article-title":"Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wildtype transthyretin","volume":"274","author":"Yazaki","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/ki.2014.368_bb0195","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3700059","article-title":"Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants","volume":"84","author":"Miller","year":"2004","journal-title":"Lab Invest"},{"key":"10.1038\/ki.2014.368_bb0200","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0205","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1038\/ki.2014.368_bb0210","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2014.368_bb0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1038\/ki.2014.368_bb0220","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","article-title":"Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity","volume":"583","author":"Ferreira","year":"2009","journal-title":"FEBS Lett"},{"key":"10.1038\/ki.2014.368_bb0225","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2014.368_bb0230","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1021\/bi1004409","article-title":"The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site","volume":"49","author":"Miyata","year":"2010","journal-title":"Biochemistry"},{"key":"10.1038\/ki.2014.368_bb0235","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"10.1038\/ki.2014.368_bb0240","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1038\/ki.2014.368_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-188-8_1","article-title":"Therapeutic oligonucleotides","volume":"764","author":"Goodchild","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1038\/ki.2014.368_bb0250","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","article-title":"Liver as a target for oligonucleotide therapeutics","volume":"59","author":"Sehgal","year":"2013","journal-title":"J Hepatol"},{"key":"10.1038\/ki.2014.368_bb0255","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/ki.2014.368_bb0260","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1073\/pnas.86.10.3474","article-title":"Characterization of oligonucleotide transport into living cells","volume":"86","author":"Loke","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2014.368_bb0265","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1101\/gad.862301","article-title":"RNA interference is mediated by 21- and 22-nucleotide RNAs","volume":"15","author":"Elbashir","year":"2001","journal-title":"Genes Dev"},{"key":"10.1038\/ki.2014.368_bb0270","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1038\/ki.2014.368_bb0275","article-title":"Advances in oligonucleotide clinical development","author":"Akshay","year":"2012"},{"key":"10.1038\/ki.2014.368_bb0280","article-title":"Targeting transthyretin for the treatment of transthyretin-associated polyneuropathy using antisense technology","author":"Guo","year":"2011"},{"key":"10.1038\/ki.2014.368_bb0285","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1038\/ki.2014.368_bb0290","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1158\/1078-0432.CCR-08-1159","article-title":"Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer","volume":"15","author":"Chia","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/ki.2014.368_bb0295","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1038\/ki.2014.368_bb0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/13506129.2012.673140","article-title":"Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy","volume":"19","author":"Ackermann","year":"2012","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1038\/ki.2014.368_bb0305","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/13506129.2011.574354075","article-title":"AA amyloidosis: potential therapy with antisense oligonucleotides","volume":"18","author":"Kluve-Beckerman","year":"2011","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0310","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.368_bb0315","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-3083.2001.00919.x","article-title":"In vitro evaluation of an enhanced human serum amyloid A (SAA2) promoter-regulated soluble TNF receptor fusion protein for anti-inflammatory gene therapy","volume":"53","author":"Rygg","year":"2001","journal-title":"Scand J Immunol"},{"key":"10.1038\/ki.2014.368_bb0320","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.0300-9475.2004.01369.x","article-title":"Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines","volume":"59","author":"Thorn","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1038\/ki.2014.368_bb0325","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.4049\/jimmunol.147.6.1803","article-title":"Sequential appearance of IL-1 and IL-6 activities in rat carrageenin-induced pleurisy","volume":"147","author":"Utsunomiya","year":"1991","journal-title":"J Immunol"},{"key":"10.1038\/ki.2014.368_bb0330","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.24735","article-title":"Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview","volume":"61","author":"Obici","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1038\/ki.2014.368_bb0335","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00005792-199107000-00002","article-title":"Secondary systemic amyloidosis: Response and survival in 64 patients","volume":"70","author":"Gertz","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"10.1038\/ki.2014.368_bb0340","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-6143.2012.04326.x","article-title":"Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance","volume":"13","author":"Pinney","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2014.368_bb0345","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1600-6143.2011.03620.x","article-title":"Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study","volume":"11","author":"Kofman","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2014.368_bb0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet"},{"key":"10.1038\/ki.2014.368_bb0355","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa065644","article-title":"Eprodisate for the treatment of renal disease in AA amyloidosis","volume":"356","author":"Dember","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.368_bb0360","first-page":"37","article-title":"Review of eprodisate for the treatment of renal disease in AA amyloidosis","volume":"5","author":"Rumjon","year":"2012","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1038\/ki.2014.368_bb0365","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/ki.2014.368_bb0370","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.368_bb0375","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","article-title":"Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis","volume":"148","author":"Gillmore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1038\/ki.2014.368_bb0380","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2014.368_bb0385","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0390","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/ki.2014.368_bb0395","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0400","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0405","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2141.2012.09080.x","article-title":"A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis","volume":"157","author":"Mollee","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1038\/ki.2014.368_bb0410","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0415","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0420","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1703200","article-title":"An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis","volume":"28","author":"Sanchorawala","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1038\/ki.2014.368_bb0425","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bmt.2010.234","article-title":"Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006","volume":"46","author":"Gertz","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1038\/ki.2014.368_bb0430","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"key":"10.1038\/ki.2014.368_bb0435","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","article-title":"Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis","volume":"109","author":"Wechalekar","year":"2007","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0440","first-page":"992","article-title":"ALchemy - a large prospective \u2018real world\u2019 study of chemotherapy in AL amyloidosis","volume":"118","author":"Lane","year":"2011"},{"key":"10.1038\/ki.2014.368_bb0445","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.368_bb0450","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1038\/ki.2014.368_bb0455","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bjh.12191","article-title":"Light chain amyloidosis 2012: a new era","volume":"160","author":"Gatt","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1038\/ki.2014.368_bb0460","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0465","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428194.2012.706287","article-title":"Molecular mechanisms of effectiveness of novel therapies in multiple myeloma","volume":"542","author":"Bianchi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/ki.2014.368_bb0470","article-title":"Investigating vulnerability to proteasome inhibition in primary light chain amyloidosis","author":"Oliva","year":"2012"},{"key":"10.1038\/ki.2014.368_bb0475","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"key":"10.1038\/ki.2014.368_bb0480","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/qjmed\/hcr105","article-title":"Velcade Can2007 Study Group. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects","volume":"104","author":"Dubrey","year":"2011","journal-title":"QJM"},{"key":"10.1038\/ki.2014.368_bb0485","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood-2012-03-413112","article-title":"CyBorD: stellar response rates in AL amyloidosis","volume":"119","author":"Merlini","year":"2012","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0490","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0495","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2014.368_bb0500","first-page":"1702","article-title":"Treatment of AL amyloidosis with bortezomib combined with alkylating agents: results from a prospective series of unselected patients","volume":"118","author":"Palladini","year":"2011"},{"key":"10.1038\/ki.2014.368_bb0505","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0510","first-page":"731","article-title":"MLN9708, an investigational oral proteasome inhibitor (PI) in relapsed or refractory light-chain (AL) amyloidosis: results of a phase I study","volume":"120","author":"Merlini","year":"2012"},{"key":"10.1038\/ki.2014.368_bb0515","doi-asserted-by":"crossref","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/ki.2014.368_bb0520","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","article-title":"Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis","volume":"92","author":"Tennent","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2014.368_bb0525","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","article-title":"Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis","volume":"417","author":"Pepys","year":"2002","journal-title":"Nature"},{"key":"10.1038\/ki.2014.368_bb0530","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1073\/pnas.0902640106","article-title":"Molecular dissection of Alzheimer\u2019s disease neuropathology by depletion of serum amyloid P component","volume":"106","author":"Kolstoe","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2014.368_bb0535","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"10.1038\/ki.2014.368_bb0540","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V86.3.855.855","article-title":"New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin","volume":"86","author":"Gianni","year":"1995","journal-title":"Blood"},{"key":"10.1038\/ki.2014.368_bb0545","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","article-title":"Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis","volume":"92","author":"Merlini","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2014.368_bb0550","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0002-9440(10)65065-1","article-title":"4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid","volume":"156","author":"Palha","year":"2000","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"10.1038\/ki.2014.368_bb0555","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815301721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815301721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T12:10:39Z","timestamp":1690719039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815301721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0085253815301721"],"URL":"https:\/\/doi.org\/10.1038\/ki.2014.368","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}